JP Morgan Chase’s Quest Diagnostics DGX Stock Holding History

JP Morgan Chase’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,600	Closed	-$1.83M	–	7507
2025 Q3	$1.83M	Sell	9,600 -31,800	-77%	-$5.64M	﹤0.01%	4150
2025 Q2	$7.44M	Buy	41,400 +39,700	+2,335%	+$6.9M	﹤0.01%	2798
2025 Q1	$288K	Buy	+1,700	New	+$279K	﹤0.01%	5080
2024 Q3	–	Sell	-25,000	Closed	-$3.42M	–	7457
2024 Q2	$3.42M	Buy	+25,000	New	+$3.42M	﹤0.01%	3338
2020 Q2	–	Sell	-25,400	Closed	-$2.04M	–	5431
2020 Q1	$2.04M	Buy	+25,400	New	+$2.63M	﹤0.01%	2950
2019 Q1	–	Sell	-60,200	Closed	-$5.01M	–	5807
2018 Q4	$5.01M	Buy	60,200 +12,600	+26%	+$1.18M	﹤0.01%	2570
2018 Q3	$5.14M	Buy	+47,600	New	+$5.22M	﹤0.01%	2728
2016 Q1	–	Sell	-1,100	Closed	-$78K	–	4713
2015 Q4	$78K	Buy	+1,100	New	+$74K	﹤0.01%	3828

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase's DGX Position: Q1 2026 in Review

JP Morgan Chase reduced its Quest Diagnostics (DGX) stake by 7.2% in Q1 2026, selling an estimated $58.2M and leaving 3,846,456 shares worth $758M. The position accounts for 0.05% of the portfolio, ranked #317.

JP Morgan Chase first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $823M in Q3 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

JP Morgan Chase held 3,846,456 shares of Quest Diagnostics worth $758M as of Q1 2026.
JP Morgan Chase sold 299,440 Quest Diagnostics shares in Q1 2026, an estimated $58.2M.
Quest Diagnostics made up 0.05% of JP Morgan Chase's portfolio in Q1 2026, its #317 holding.
JP Morgan Chase first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
JP Morgan Chase's Quest Diagnostics position peaked at $823M in Q3 2025.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.